Foghorn Therapeutics (FHTX) Q4 2024 Annual Earnings
FHTX·Reported March 6, 2025·Before market open
Foghorn Therapeutics reported Q4 2024 revenue of $2.9M, missed analyst consensus of $8.7M by $5.8M. Diluted EPS came in at $-0.30, beat the $-0.43 consensus by $0.13.
Revenue
$2.9Mmissed by $5.8M
Consensus: $8.7MDiluted EPS
$-0.30beat by $0.13
Consensus: $-0.43
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Foghorn Therapeutics's Q4 2024 earnings report.
Foghorn Therapeutics (FHTX) reported Q4 2024 earnings on March 6, 2025 before market open.
Foghorn Therapeutics reported revenue of $2.9M and diluted EPS of $-0.30 for Q4 2024.
Revenue missed the consensus estimate of $8.7M by $5.8M. EPS beat the consensus estimate of $-0.43 by $0.13.
You can read the 10-K periodic report (0001628280-25-010933) directly on SEC EDGAR. The filing index links above go to sec.gov.